Kidney Week Humacyte ( (HUMA) ) has shared an announcement. Humacyte, Inc. has initiated a registered direct offering of approximately $30.0 million in common stock and warrants to an ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

Humacyte Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -41.67%. The profit margin, also known as the revenue ...

Positive results from ongoing non-human primate studies support the potential ... partly offset by decreases in non-cash stock compensation expense and insurance expense. Other net expense was ...

Humacyte (NASDAQ:HUMA) stock fell 18% in after-hours trading Friday after the company said the FDA has informed the company ...

Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma ... 8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% Macro environment favors large-caps, but ...

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a ...

When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.